MoonLake Immunotherapeutics will host an Investor Day on February 23, 2026, at 8 am EST / 2 pm CET to discuss outcomes from a recent Type B FDA meeting, share new clinical data for SLK across indications, and provide details on the company's catalyst calendar for 2026 and beyond.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001158301-en) on January 08, 2026, and is solely responsible for the information contained therein.